Latest Pharma Insights
Respiratory Feats Put Glenmark’s US Recovery On Firmer Footing
Glenmark’s US recovery accelerated in Q1 FY27 as respiratory launches drove nearly 20% underlying growth, with further approvals expected in the second half and management forecasting sustained momentum.
Generics Bulletin - August 14, 2026
Glenmark’s US recovery accelerated in Q1 FY27 as respiratory launches drove nearly 20% underlying growth, with further approvals expected in the second half and management forecasting sustained momentum.
Generics Bulletin - August 14, 2026
GSK India Portfolio Pivot Gathers Pace, Blenrep Poised As Oncology ‘Arrowhead’
GSK India sharpens its specialty thrust with a string of oncology and vaccine launches lined up as the company aligns with the group’s wider global strategy while also holding ground on its general medicines base.
Scrip - August 14, 2026
GSK India sharpens its specialty thrust with a string of oncology and vaccine launches lined up as the company aligns with the group’s wider global strategy while also holding ground on its general medicines base.
Scrip - August 14, 2026
EU PPWR Labeling For Medtech: New Symbols, Old Space Problem
The PPWR bolts new packaging-labeling duties onto device packs already governed by the MDR and IVDR. Manufacturer identification kicks in from Aug. 12; harmonized material and sorting pictograms follow from 2028. Experts told Medtech Insight the hardest part is finding room for it all.
Medtech Insight - August 14, 2026
The PPWR bolts new packaging-labeling duties onto device packs already governed by the MDR and IVDR. Manufacturer identification kicks in from Aug. 12; harmonized material and sorting pictograms follow from 2028. Experts told Medtech Insight the hardest part is finding room for it all.
Medtech Insight - August 14, 2026
Alfasigma Continues Expansion With Nordic Deal
Following a share purchase agreement between Italian firm Alfasigma and Nordic Group B.V, Alfasigma is set to acquire 100% of shares in the Nordic group and its subsidiaries, widening its specialty portfolio.
Generics Bulletin - August 14, 2026
Following a share purchase agreement between Italian firm Alfasigma and Nordic Group B.V, Alfasigma is set to acquire 100% of shares in the Nordic group and its subsidiaries, widening its specialty portfolio.
Generics Bulletin - August 14, 2026
Spending More To Produce Less? How Industry Productivity Is Really Faring
Norstella’s new Pipeline-to-Patient Productivity Index promises to give the most comprehensive assessment of pharma productivity yet – its inaugural findings capture the many moving parts in getting novel drugs to patients and the scale of the challenges facing the industry.
Scrip - August 14, 2026
Norstella’s new Pipeline-to-Patient Productivity Index promises to give the most comprehensive assessment of pharma productivity yet – its inaugural findings capture the many moving parts in getting novel drugs to patients and the scale of the challenges facing the industry.
Scrip - August 14, 2026
Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
France’s model of incentivizing biosimilars substitution to aid innovator drug purchases could be worthy of emulation while Germany’s recently announced changes cut both ways, says Lupin’s CEO Vinita Gupta as she also talks of South Africa semaglutide launch plans.
Generics Bulletin - August 14, 2026
France’s model of incentivizing biosimilars substitution to aid innovator drug purchases could be worthy of emulation while Germany’s recently announced changes cut both ways, says Lupin’s CEO Vinita Gupta as she also talks of South Africa semaglutide launch plans.
Generics Bulletin - August 14, 2026
G&W Must Face Jury Over Alleged Generics Price-Fixing Conspiracy
G&W Laboratories has failed to escape the states’ wider generics price-fixing case, leaving allegations over an overarching conspiracy and key product-specific claims for a jury to consider in February 2027.
Generics Bulletin - August 14, 2026
G&W Laboratories has failed to escape the states’ wider generics price-fixing case, leaving allegations over an overarching conspiracy and key product-specific claims for a jury to consider in February 2027.
Generics Bulletin - August 14, 2026
Novartis Keeps UK Entresto Generics At Bay Until 2028
Accord has failed to clear the way for its planned UK generic Entresto launch after the High Court upheld Novartis’ patent and SPC, although one of the generics firm’s validity attacks came close to succeeding.
Generics Bulletin - August 14, 2026
Accord has failed to clear the way for its planned UK generic Entresto launch after the High Court upheld Novartis’ patent and SPC, although one of the generics firm’s validity attacks came close to succeeding.
Generics Bulletin - August 14, 2026
Sumitomo Rebuts Gotham’s Accounting ‘Black Hole’ Allegations
Sumitomo Pharma has had to address allegations relating to its accounting practices from US investment company Gotham City Research, which charges the Japanese firm inflated earnings.
Scrip - August 14, 2026
Sumitomo Pharma has had to address allegations relating to its accounting practices from US investment company Gotham City Research, which charges the Japanese firm inflated earnings.
Scrip - August 14, 2026
GSK India Portfolio Pivot Gathers Pace, Blenrep Poised As Oncology ‘Arrowhead’
GSK India sharpens its specialty thrust with a string of oncology and vaccine launches lined up as the company aligns with the group’s wider global strategy while also holding ground on its general medicines base.
Scrip - August 14, 2026
GSK India sharpens its specialty thrust with a string of oncology and vaccine launches lined up as the company aligns with the group’s wider global strategy while also holding ground on its general medicines base.
Scrip - August 14, 2026
Spending More To Produce Less? How Industry Productivity Is Really Faring
Norstella’s new Pipeline-to-Patient Productivity Index promises to give the most comprehensive assessment of pharma productivity yet – its inaugural findings capture the many moving parts in getting novel drugs to patients and the scale of the challenges facing the industry.
Scrip - August 14, 2026
Norstella’s new Pipeline-to-Patient Productivity Index promises to give the most comprehensive assessment of pharma productivity yet – its inaugural findings capture the many moving parts in getting novel drugs to patients and the scale of the challenges facing the industry.
Scrip - August 14, 2026
Sumitomo Rebuts Gotham’s Accounting ‘Black Hole’ Allegations
Sumitomo Pharma has had to address allegations relating to its accounting practices from US investment company Gotham City Research, which charges the Japanese firm inflated earnings.
Scrip - August 14, 2026
Sumitomo Pharma has had to address allegations relating to its accounting practices from US investment company Gotham City Research, which charges the Japanese firm inflated earnings.
Scrip - August 14, 2026
EU PPWR Labeling For Medtech: New Symbols, Old Space Problem
The PPWR bolts new packaging-labeling duties onto device packs already governed by the MDR and IVDR. Manufacturer identification kicks in from Aug. 12; harmonized material and sorting pictograms follow from 2028. Experts told Medtech Insight the hardest part is finding room for it all.
Medtech Insight - August 14, 2026
The PPWR bolts new packaging-labeling duties onto device packs already governed by the MDR and IVDR. Manufacturer identification kicks in from Aug. 12; harmonized material and sorting pictograms follow from 2028. Experts told Medtech Insight the hardest part is finding room for it all.
Medtech Insight - August 14, 2026
Dove Courts US Open Fans, Degree Hits NYC Subway With Summer Campaigns
Unilever is running simultaneous summer campaigns for its Dove and Degree deodorant brands, targeting US Open tennis fans and New York City subway commuters.
HBW Insight - August 13, 2026
Unilever is running simultaneous summer campaigns for its Dove and Degree deodorant brands, targeting US Open tennis fans and New York City subway commuters.
HBW Insight - August 13, 2026
US FDA ‘Simple Reform’ Reorg Approved; Inspection ‘Generalist’ Changes Coming Later
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
HBW Insight - August 13, 2026
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
HBW Insight - August 13, 2026
Remediation At Major Production Facility Puts Spotlight On One-Third of Amphastar Sales
Amphastar braces for higher costs and some sales pressure as it remediates a production facility, while newer generics support growth and it keeps its insulin aspart biosimilar on track for potential 2027 launch.
HBW Insight - August 13, 2026
Amphastar braces for higher costs and some sales pressure as it remediates a production facility, while newer generics support growth and it keeps its insulin aspart biosimilar on track for potential 2027 launch.
HBW Insight - August 13, 2026
The Self-Care Confidence Gap: Pharmacists Struggle Most Where Industry Is Growing Fastest
An Opella-funded FIP survey shows pharmacists' confidence in advising consumers is highest for mature categories like pain and fever and lowest in liver health, sleep, weight management and other areas where OTC companies are growing fastest.
HBW Insight - August 13, 2026
An Opella-funded FIP survey shows pharmacists' confidence in advising consumers is highest for mature categories like pain and fever and lowest in liver health, sleep, weight management and other areas where OTC companies are growing fastest.
HBW Insight - August 13, 2026
Respiratory Feats Put Glenmark’s US Recovery On Firmer Footing
Glenmark’s US recovery accelerated in Q1 FY27 as respiratory launches drove nearly 20% underlying growth, with further approvals expected in the second half and management forecasting sustained momentum.
Generics Bulletin - August 14, 2026
Glenmark’s US recovery accelerated in Q1 FY27 as respiratory launches drove nearly 20% underlying growth, with further approvals expected in the second half and management forecasting sustained momentum.
Generics Bulletin - August 14, 2026
Alfasigma Continues Expansion With Nordic Deal
Following a share purchase agreement between Italian firm Alfasigma and Nordic Group B.V, Alfasigma is set to acquire 100% of shares in the Nordic group and its subsidiaries, widening its specialty portfolio.
Generics Bulletin - August 14, 2026
Following a share purchase agreement between Italian firm Alfasigma and Nordic Group B.V, Alfasigma is set to acquire 100% of shares in the Nordic group and its subsidiaries, widening its specialty portfolio.
Generics Bulletin - August 14, 2026
Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
France’s model of incentivizing biosimilars substitution to aid innovator drug purchases could be worthy of emulation while Germany’s recently announced changes cut both ways, says Lupin’s CEO Vinita Gupta as she also talks of South Africa semaglutide launch plans.
Generics Bulletin - August 14, 2026
France’s model of incentivizing biosimilars substitution to aid innovator drug purchases could be worthy of emulation while Germany’s recently announced changes cut both ways, says Lupin’s CEO Vinita Gupta as she also talks of South Africa semaglutide launch plans.
Generics Bulletin - August 14, 2026
G&W Must Face Jury Over Alleged Generics Price-Fixing Conspiracy
G&W Laboratories has failed to escape the states’ wider generics price-fixing case, leaving allegations over an overarching conspiracy and key product-specific claims for a jury to consider in February 2027.
Generics Bulletin - August 14, 2026
G&W Laboratories has failed to escape the states’ wider generics price-fixing case, leaving allegations over an overarching conspiracy and key product-specific claims for a jury to consider in February 2027.
Generics Bulletin - August 14, 2026
Novartis Keeps UK Entresto Generics At Bay Until 2028
Accord has failed to clear the way for its planned UK generic Entresto launch after the High Court upheld Novartis’ patent and SPC, although one of the generics firm’s validity attacks came close to succeeding.
Generics Bulletin - August 14, 2026
Accord has failed to clear the way for its planned UK generic Entresto launch after the High Court upheld Novartis’ patent and SPC, although one of the generics firm’s validity attacks came close to succeeding.
Generics Bulletin - August 14, 2026
The Protocol Is The Problem – And The Answer Lies In Its Digital Twin
AI-powered simulation is moving clinical trial design from historical precedent to predictive engineering. The implications for sponsors and CROs are significant.
In Vivo - August 13, 2026
AI-powered simulation is moving clinical trial design from historical precedent to predictive engineering. The implications for sponsors and CROs are significant.
In Vivo - August 13, 2026